---
schema_version: "secwatch.filing_event.v1"
accession: "0002007919-25-000097"
form_type: "8-K"
ticker: "INBX"
cik: "0002007919"
company_name: "Inhibrx Biosciences, Inc."
filed_at: "2025-12-16T23:59:59+00:00"
generated_at: "2026-05-16T13:06:19.708683+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Inhibrx provides INBRX-106 and ozekibart trial updates; Ewing sarcoma FDA meeting planned for H2 2026

## Summary
- INBRX-106 HNSCC Phase 2/3: 46 of 60 patients enrolled; completion expected Q1 2026.
- NSCLC Phase 1/2 trial completed enrollment of 34 patients in Nov 2025; data immature.
- Ozekibart colorectal cancer expansion cohort enrolled 44 patients; PFS data mature Q2 2026.
- Ewing sarcoma trial enrollment expected Q2 2026; FDA meeting for accelerated approval planned H2 2026 if trends continue.
- No efficacy data released; management cautions datasets lack maturity for conclusions.

## SEC filing metadata
- accession: 0002007919-25-000097
- form_type: 8-K
- ticker: INBX
- cik: 0002007919
- company_name: Inhibrx Biosciences, Inc.
- filed_at: 2025-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2007919/000200791925000097/0002007919-25-000097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2007919/000200791925000097/inhibrx-20251216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002007919-25-000097
- JSON: https://secwatch.observer/filing/0002007919-25-000097.json
- Plain text: https://secwatch.observer/filing/0002007919-25-000097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.